A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.


Updates from The Motley Fool

Latest updates on Alnylam Pharmaceuticals from Fool.com.


Stock Performance

ALNY vs. S&P 500 | 2 Year Performance
View Interactive ALNY Charts
Sponsored by

Key Data Points

Primary metrics and data points about Alnylam Pharmaceuticals.
Current Price: $69.94
Prev Close: $76.67
Open: $75.00
Bid: $69.54
Ask: $70.00
Day's Range: $69.77 - $75.35
52wk Range: $49.96 - $110.75
Volume: 1,363,839
Avg Vol 478,947
Market Cap: $5.93B
P/E (ttm): -18.08
EPS (ttm): -$4.24
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Alnylam Pharmaceuticals.
CAPS Rating 4 out of 5
 
380 Outperform
38 Underperform
CAPS All Stars
 
83 Outperform
17 Underperform

How do you think Alnylam Pharmaceuticals will perform against the market?



You pick for Alnylam Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

John M. Maraganore, CEO

88% Approve

Based on 14 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Alnylam Pharmaceuticals.

A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers